Greg Andrew Durm

777 total citations
52 papers, 488 citations indexed

About

Greg Andrew Durm is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Greg Andrew Durm has authored 52 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Greg Andrew Durm's work include Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Colorectal Cancer Treatments and Studies (16 papers). Greg Andrew Durm is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (25 papers) and Colorectal Cancer Treatments and Studies (16 papers). Greg Andrew Durm collaborates with scholars based in United States, Australia and South Korea. Greg Andrew Durm's co-authors include Nasser H. Hanna, Sandra K. Althouse, Salma K. Jabbour, Shadia I. Jalal, Goetz Kloecker, Ebenezer A. Kio, Robin Zoň, Karen L. Reckamp, Ryan D. Gentzler and Ahad A. Sadiq and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Greg Andrew Durm

47 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Greg Andrew Durm United States 11 375 324 97 60 56 52 488
Zhenkui Pan China 10 312 0.8× 302 0.9× 74 0.8× 50 0.8× 80 1.4× 12 423
Emily Roarty United States 10 348 0.9× 330 1.0× 79 0.8× 54 0.9× 138 2.5× 24 480
M. D’Arcangelo Italy 12 200 0.5× 196 0.6× 119 1.2× 41 0.7× 79 1.4× 31 360
Jessica Salvini Italy 3 460 1.2× 339 1.0× 93 1.0× 96 1.6× 90 1.6× 4 551
Chester Kao United States 8 164 0.4× 160 0.5× 110 1.1× 43 0.7× 108 1.9× 19 330
M.V. Bluthgen France 8 243 0.6× 238 0.7× 98 1.0× 28 0.5× 180 3.2× 18 424
Beung‐Chul Ahn South Korea 12 497 1.3× 366 1.1× 106 1.1× 106 1.8× 81 1.4× 38 621
Ilze Bāra United States 9 260 0.7× 225 0.7× 57 0.6× 40 0.7× 38 0.7× 22 365
L. Paz-Ares Spain 9 291 0.8× 215 0.7× 97 1.0× 25 0.4× 40 0.7× 51 374
Tor Audun Klingen Norway 11 197 0.5× 134 0.4× 64 0.7× 66 1.1× 81 1.4× 21 353

Countries citing papers authored by Greg Andrew Durm

Since Specialization
Citations

This map shows the geographic impact of Greg Andrew Durm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Andrew Durm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Andrew Durm more than expected).

Fields of papers citing papers by Greg Andrew Durm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Andrew Durm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Andrew Durm. The network helps show where Greg Andrew Durm may publish in the future.

Co-authorship network of co-authors of Greg Andrew Durm

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Andrew Durm. A scholar is included among the top collaborators of Greg Andrew Durm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Andrew Durm. Greg Andrew Durm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leighl, Natasha B., Nofisat Ismaila, Greg Andrew Durm, et al.. (2025). Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3. Journal of Clinical Oncology. 43(10). e17–e30. 5 indexed citations
2.
3.
Furqan, Muhammad, Lawrence Feldman, Greg Andrew Durm, et al.. (2025). 2761O Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer. Annals of Oncology. 36. S1369–S1370.
4.
Ulahannan, Susanna V., Thomas U. Marron, Haeseong Park, et al.. (2024). Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 2524–2524. 2 indexed citations
5.
Kennedy, Eugene P., Greg Andrew Durm, & Janice L. Farlow. (2024). Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists. OTO Open. 8(4). e70040–e70040. 1 indexed citations
6.
Weisman, Michael, Greg Andrew Durm, Misty Dawn Shields, et al.. (2024). Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 121(3). 720–727. 4 indexed citations
7.
Durm, Greg Andrew, Angela Bik‐Yu Hui, Sha Cao, et al.. (2024). Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 19(10). 1427–1437. 9 indexed citations
8.
9.
Hanna, Nasser H., et al.. (2021). Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC. JCO Oncology Practice. 17(8). 472–474. 7 indexed citations
10.
11.
12.
Hong, David S., Y-J. Bang, Fabrice Barlési, et al.. (2020). 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Annals of Oncology. 31. S812–S812. 6 indexed citations
13.
Strickler, John H., Marwan Fakih, Jayesh Desai, et al.. (2020). SO-24 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial. Annals of Oncology. 31. S226–S226. 2 indexed citations
14.
Hong, David S., Y-J. Bang, Fabrice Barlési, et al.. (2020). 381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Annals of Oncology. 31. S1389–S1390. 2 indexed citations
15.
16.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1125–S1126. 3 indexed citations
17.
Durm, Greg Andrew, Sandra K. Althouse, Salma K. Jabbour, et al.. (2019). P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Journal of Thoracic Oncology. 14(10). S627–S627. 1 indexed citations
18.
Althouse, Sandra K., et al.. (2019). Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation Pembrolizumab: a subset analysis of a phase II study from the Hoosier Cancer Research Network LUN 14-179. Publisher. 2 indexed citations
19.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology. 14(10). S208–S208. 30 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenkui Pan Breakdown of academic impact, for papers by Emily Roarty Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Jessica Salvini Breakdown of academic impact, for papers by Chester Kao Breakdown of academic impact, for papers by M.V. Bluthgen Breakdown of academic impact, for papers by Beung‐Chul Ahn Breakdown of academic impact, for papers by Ilze Bāra Breakdown of academic impact, for papers by L. Paz-Ares Breakdown of academic impact, for papers by Tor Audun Klingen
Rankless by CCL
2026